• E-mailRuth.Brenk@uib.no
  • Phone+47 55 58 60 70+47 960 40 226
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen

Our overall research goal is to improve methods used for structure-based drug design and to apply these methods to design inhibitors for enzymes with biological relevance. A key point in our research is the interplay of theoretical and experimental methods.

To read more about what we do, check out our homepage .


For a full list of publications click here.

Academic article
  • Irsheid, Lina; Wehler, Thomas Martin; Borek, Christoph; Kiefer, Werner; Brenk, Ruth; Ortiz-Soto, Maria Elena; Seibel, Jurgen; Schirmeister, Tanja. 2019. Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design. PLOS ONE. 1-19.
  • Kersten, Christian; Fleischer, Edmond; Kehrein, Josef; Borek, Christoph; Jaenicke, Elmar; Sotriffer, Christoph; Brenk, Ruth. 2019. How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System. Journal of Medicinal Chemistry.
  • Klein, Raphael; Linciano, Pasquale; Celenza, Guiseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazques, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Donatella. 2018. In silico identification and experimental validation of hits active against KPC-2 β-lactamase. PLOS ONE.
  • Sarkar, Aurijit; Brenk, Ruth. 2015. To hit or not to hit, that is the question -genome-wide structure-based druggability predictions for pseudomonas aeruginosa proteins. PLOS ONE.
Academic literature review
  • Rekand, Illimar Hugo; Brenk, Ruth. 2017. Ligand design for riboswitches, an emerging target class for novel antibiotics. 1649-1662.
  • Wehler, Thomas; Brenk, Ruth. 2017. Structure-Based Discovery of Small Molecules Binding to RNA. . In:
    • Garner, Amanda. 2017. RNA Therapeutics. Springer.

More information in national current research information system (CRIStin)

Research groups